Search

Displaying results 2981 - 2990 of 8974 in total
  1. Drug

    alpha-Linolenic acid

    go.drugbank.com/drugs/DB00132
    ApprovedInvestigationalNutraceuticalWithdrawn

    It is a component of many common vegetable oils and is important to human nutrition.

    Mixtures: SIMILAC ALIMENTUM 400 G TOZ
  2. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.

  3. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  4. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

  5. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    one to three prior therapies. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.

  6. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

  7. Drug

    Aminopterin

    go.drugbank.com/drugs/DB08878
    ApprovedWithdrawn

    Clinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.

  8. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

  9. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

    Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.